Fight Infections Foundation and IrsiCaixa Identify Viral Evolution as the Primary Driver of Reinfections
Fight Infections Foundation and IrsiCaixa, in collaboration with the Germans Trias Hospital, have published a study in the scientific journal Viruses indicating that viral evolution is the primary driver of reinfections. In Catalonia, where an estimated incidence of 78 cases per 100,000 inhabitants has been reached, researchers found that the emergence of new variants like Delta and Omicron is directly associated with the ability of the virus to evade prior immunity.
The Role of B Cells in Neutralizing Antiviral Defenses
A research team has uncovered why the COVID-19 virus proved so deadly, causing at least three million deaths worldwide according to World Health Organization (WHO) estimates. New research examining type I interferons—signaling proteins that act as an early warning system to trigger antiviral defenses—has identified why this critical response failed in some patients.
As detailed in Cell (DOI: 10.1016/j.cell.2026.04.013) on July 19, 2026, the study found that these essential proteins were unable to effectively combat the coronavirus because affected patients harbored a large and diverse population of B cells that target the interferons themselves. This pre-existing autoimmunity leaves individuals susceptible to severe viral infections.
La Trobe University and WEHI Researchers Discover SARS-CoV-2 Hiding in Apoptotic Bodies
Hidden Viral Transmission and Metabolic Pathways
Research published in Nature Communications by La Trobe University and WEHI researchers identified a hidden pathway allowing the virus to infect the immune system. The study found that SARS-CoV-2 can hide inside apoptotic bodies (ApoBDs), which are tiny fragments of dying infected cells. Lead researcher Dr. Kha Phan, a National Health and Medical Research Centre (NHMRC) Emerging Leadership Fellow at the La Trobe Institute for Molecular Science (LIMS), explained that immune cells called macrophages "eat" these particles as part of the body’s normal housekeeping process, which allows the virus to enter and spread between cells and triggers damaging inflammation in the lungs.
Separately, a study evaluating genetic variants in the PI3K/AKT/mTOR metabolic pathway examined 216 mild and 291 severe COVID-19 patients. Researchers focused on variants rs3730089 (PIK3R1), rs785468 (PIK3R3), and rs11121484 (PIK3CD). The study found that the C allele of rs11121484 was associated with susceptibility to severe disease, while rs785468 and rs3730089 correlated with higher mortality risk. Patients with the GG genotype of rs3730089 exhibited increased levels of the inflammatory cytokine IL-6.
Stanford Medicine Researchers Link Epstein-Barr Virus to Multiple Sclerosis Onset
Immune Resilience and Cross-Reactivity
Researchers from The University of Texas Health Science Center at San Antonio, working with collaborators in five countries, have identified "immune resilience"—the capacity to recover from inflammatory stress—as a factor influencing COVID-19 mortality, HIV/AIDS, and sepsis. Published in Nature Communications and supported by the National Institute of Allergy and Infectious Diseases (NIAID), the study developed metrics to quantify this resilience, which will aid in healthcare decisions.
Furthermore, a study published Jan. 24 in Nature by Stanford Medicine researchers proved that the Epstein-Barr virus (EBV) can prime the immune system to attack the nervous system, potentially triggering multiple sclerosis. William Robinson, MD, PhD, professor of immunology and rheumatology at Stanford, noted that approximately 20% to 25% of multiple sclerosis patients have antibodies that bind to both the EBV protein EBNA1 and a host protein called GlialCAM. "Part of the EBV protein mimics your own host protein — in this case, GlialCAM, found in the insulating sheath on nerves," Robinson stated.
Manish Butte and UCLA Lead Global Data Integration Efforts
Global Data Integration
To increase the impact of these efforts, scientists are integrating data into global consortia, including the COVID Human Genetic Effort and the COVID-19 Host Genetics Initiative. Manish Butte, UCLA’s E. Richard Stiehm Professor of Pediatric Allergy, Immunology and Rheumatology, emphasized the necessity of this cooperation. "The amazing thing that is happening right now is that everyone is sharing their data as openly and quickly as they can," Butte said. "What we are doing is not just going to help patients of the UCLA Health system. It will really impact the whole world."
Sources: News Medical, Irsicaixa.
Worth a look
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.